Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.
<h4>Introduction</h4>Thrombotic thrombocytopenic purpura (TTP) is a diagnostic and therapeutic emergency. Therapeutic plasma exchange (TPE) combined with immunosuppression has been the cornerstone of the initial management. To produce optimal benefits, emerging treatments must be used ag...
Guardado en:
Autores principales: | Andry Van de Louw, Eric Mariotte, Michael Darmon, Austin Cohrs, Douglas Leslie, Elie Azoulay |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/df514f54a2344415b52ce37799b62a31 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions
por: Lemiale V, et al.
Publicado: (2021) -
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Flora Peyvandi, et al.
Publicado: (2021) -
THROMBOTIC THROMBOCYTOPENIC PURPURA: OUR CLINICAL EXPERIENCE
por: Zahid Farooq Baig, et al.
Publicado: (2018) -
Emerging Concepts in Immune Thrombotic Thrombocytopenic Purpura
por: Aicha Laghmouchi, et al.
Publicado: (2021) -
COVID-19 and thrombotic thrombocytopenic purpura: A review of literature
por: Balraj Singh, et al.
Publicado: (2021)